MedTrace Logo

Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology

NCT01760291 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 576

Last updated 2022-03-29

Study results available
· View outcomes & findings →

Summary

To provide additional information about the safety and efficacy of the WATCHMAN LAA Closure Technology

Conditions

Interventions

DEVICE

WATCHMAN LAA Closure Technology

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Saibal Kar, M.D. · Cedars-Sinai Medical Center

  • Shephal Doshi, M.D. · Pacific Heart

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01760291 on ClinicalTrials.gov